Klein Hersh Blog

Reflections on 2020 and an Optimistic Outlook for the Year Ahead

By Jesse Klein, Jason Hersh, and Josh Albert We’ve just reached the end of a year unlike any other. As we look back on challenges faced and what has been accomplished over the last 12 months, there are many things to take with us into 2021. We continued to be amazed by the pace of scientific discovery.  The value of ...
January 28, 2021

The Cell and Gene Therapy Revolution

A conversation with Klein Hersh’s Hillary Kaplan Even as the global biopharma industry urgently focuses on combatting COVID-19, the cell/gene therapy sector marches onward, experiencing strong growth and expansion. The sector has continued its rapid progression into one of the industry’s hottest markets, spurred on by robust venture capital investment in new company formation and ongoing strategic acquisitions by big ...
September 24, 2020

Common Questions in the Search Process: Advice for Candidates

In helping organizations across the healthcare industry build their analytics and data science teams, I’ve had the opportunity to connect with thousands of job candidates. During these countless conversations, I’ve come across some tough, but common questions that many candidates have, but are unsure how to address with prospective employers. Here are answers to five commonly asked questions that candidates ...
September 10, 2020

The Skyrocketing Growth of Telehealth: The Healthcare Sector Adapts to Change Amid COVID-19

There is no doubt that we are all living history as we face the COVID-19 pandemic. And while every industry has been impacted by this enormous global challenge, there are some, particularly those surrounding healthcare and technology, that are experiencing record surge due to significant need. Telehealth and virtual care have been brewing in the background for years, but the ...
July 8, 2020

Changing Role of the Quality Professional in Pharma’s New Era

Drug discovery and manufacturing is rapidly changing across the pharmaceutical industry. The increased focus on rare diseases, along with breakthroughs in biologics, gene and cell therapy, and other forms of personalized medicine, have empowered bold innovation among drug developers. Many companies are leveraging these scientific advancements to pursue a new aspirational focus on finding cures for the most-difficult-to-treat diseases. As ...
January 18, 2020

Meeting the Growing Talent Demand in Cell and Gene Therapy & Biologics

Boom in cell and gene therapy Among these segments is cell and gene therapy, where innovative science in areas such as cardiovascular disease, cancer, and genetic disorders is driving rapid R&D activity to address critical unmet patient needs. Recent scientific successes in cell and gene therapy are fostering robust venture investment in start-ups, as well as a flurry of mergers ...
October 1, 2019

The Talent Prescription for Generics and Specialty Pharma

Among the hot topics dominating the buzz at the J.P. Morgan Healthcare Conference earlier this year, high on the list were the profound changes impacting generics and specialty pharma. At the conference, I spoke with executives from companies across each of these industry segments and discussed the unique challenges affecting their business. During these conversations, each executive had one common ...
March 13, 2019

Qualifying a Search Partner: How to Save Time and Reduce Risk

At the recent HLTH healthcare industry conference in Las Vegas, I had the opportunity to meet with the chief executive officer (CEO) of a prominent venture capital-backed digital health company. As we talked about the hiring needs for her team, she discussed one of the struggles she was having with the recruiting process: “Hiring top executive talent is so critical, ...
September 5, 2018

Winning the Race for Top Medical Talent

Robust capital investment is driving extraordinary growth in the life sciences industry. According to Pitchbook, a researcher covering the venture and private equity markets, $2.8 billion has already been invested in pharma and biotech startups in the first quarter of 2018. This investment level is on track to eclipse the record $10 billion that was invested in 2017. New companies ...
July 16, 2018

The Business Case for HEOR and Market Access in Earlier Stage Biopharma Companies

The rising costs of prescription drugs and healthcare delivery is impacting the way the pharmaceutical industry brings new medicines to market. Today, key healthcare stakeholders from the, payer, provider, accountable care organization (ACO), pharmacy benefit manager (PBM), and patient communities are playing an increased role in determining the market access strategies for new drugs.   Concerned with a myriad of ...
May 11, 2018